Here, we report proteomic analyses of 129 human cortical tissues to define changes
associated with the asymptomatic and symptomatic stages of Alzheimer's disease (AD) …

Neurodegenerative diseases are a growing burden, and there is an urgent need for better
biomarkers for diagnosis, prognosis, and treatment efficacy. Structural and functional brain …

Amyloid-beta (Aβ) plays a key role in the pathogenesis of Alzheimer's disease (AD), but little
is known about the proteoforms present in AD brain. We used high-resolution mass …

Alzheimer's disease is biologically heterogeneous, and detailed understanding of the
processes involved in patients is critical for development of treatments. CSF contains …

Introduction Alzheimer's disease (AD) is the most common cause of dementia, characterized
by progressive cognitive decline. Protein biomarkers of AD brain pathology, including β …

Aptamer-based proteomics revealed differentially abundant proteins in Alzheimer's disease
(AD) brains in the Baltimore Longitudinal Study of Aging and Religious Orders Study (mean …

Blood-based biomarkers represent a less invasive and potentially cheaper approach for
aiding Alzheimer's disease (AD) detection compared with cerebrospinal fluid and some …

Alzheimer's disease (AD) is characterized by brain protein aggregates of amyloid-β (Aβ) and
phosphorylated tau (pTau) that become plaques and tangles, and dystrophic neurites …

Alzheimer's disease (AD) is a heterogeneous disorder with abnormalities in multiple
biological domains. In an advanced machine learning analysis of postmortem brain and in …

Patients with Alzheimer's disease (AD) and Parkinson's disease (PD) often have overlap in
clinical presentation and brain neuropathology suggesting that these two diseases share …